Document:

Exhibit 10.37

 

AGREEMENT OF TERMINATION, COMPROMISE, SETTLEMENT

AND MUTUAL RELEASE OF CLAIMS

This AGREEMENT OF TERMINATION, COMPROMISE, SETTLEMENT, AND MUTUAL RELEASE OF CLAIMS (this "Agreement") is entered into effective March 31, 2016 (the "Effective Date") by CANNASYS, INC., a Nevada corporation ("CannaSys"), on the one hand, and by LUVBUDS, LLC, a Colorado limited liability company ("LuvBuds"), BRETT HARRIS, an individual residing in Denver, Colorado ("Harris"), and TAG DISTRIBUTING LLC, a Delaware limited liability company doing business in Colorado under the trade name CONSIGLIERE INC. ("Consigliere"), on the other hand. Each person or entity may be referred to as a "Party" and collectively as the "Parties." This Agreement is effective on the date of the signature by all Parties.

Recitals

A. On December 17, 2015, CannaSys, LuvBuds, and Harris entered into an Asset Purchase Agreement under which CannaSys purchased the assets related to LuvBuds' business and 70% of the membership interest in LuvBuds from Harris and LuvBuds (the "APA"). The purchase price for the assets and membership interest was 300,000 shares of CannaSys common stock and a cash payment of $25,000. CannaSys issued a stock grant for 300,000 shares of CannaSys common stock to Harris, and the cash payment was not made on its due date.

B. On January, 24, 2016, CannaSys entered into a Consulting Agreement with Consigliere whereby CannaSys engaged Consigliere and its principal Harris to provide consulting services for CannaSys (the "Consulting Agreement").

C. Disputes have arisen among the Parties respecting the APA and Consulting Agreement and the relationships among the Parties.

D. The Parties, without admitting liability, wish to enter into this Agreement to terminate the APA and Consulting Agreement and to resolve, compromise, settle, and dispose of and any and all disputes and claims that exist or may exist among them.

Agreement

NOW, THEREFORE, in consideration of the mutual promises, covenants, conditions, and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. Termination. The Parties hereby agree that as of the Effective Date, the APA and Consulting Agreement shall each terminate, and thereafter, each agreement shall have no further force or effect. The Parties will not be liable for any ongoing obligations under the agreements except as expressly set forth in this Agreement.

2. Issuance of CannaSys Common Stock to Harris. Subject to the terms of this Agreement, Harris can retain the stock grant for 300,000 shares of CannaSys common stock granted to him on February 4, 2016.

1

3. Issuance of CannaSys Common Stock to Consigliere. Subject to the terms of this Agreement, Consigliere can retain the warrant for 100,000 shares of CannaSys common stock issued to it on January 24, 2016.

4. Assignment and Assumption of LuvBuds' Membership Interest. CannaSys hereby sells, transfers, and sets over to Harris, free and clear of any and all liens that may have arisen between December 18, 2015 and the Effective Date, all of CannaSys's right, title, and interest in and to the 70% membership interest in LuvBuds. Harris hereby accepts the membership interest and assumes the obligations and duties relating to the membership interest arising after the Effective Date.

5. Assignment and Assumption of LuvBuds' Assets. CannaSys hereby sells, transfers, and sets over to LuvBuds, free and clear of any and all liens that may have arisen between December 18, 2015 and the Effective Date, all of CannaSys's right, title, and interest in and to the Acquired Assets (as defined in the APA) and any additional assets acquired by LuvBuds between December 18, 2015 and the Effective Date. LuvBuds hereby accepts the Acquired Assets and additional assets and assumes the obligations and duties under the Acquired Assets, additional assets, and Assumed Liabilities (as defined in the APA) arising after the Effective Date.

6. Mutual Release. Each Party, for itself and its successors, assigns, shareholders, officers, directors, employees, agents, members, managers, and other representatives hereby completely, unconditionally, and forever releases, acquits, and discharges each other Party, and its respective affiliated entities, current and former agents and employees, attorneys, officers, directors, managers, members, shareholders, insurers, successors, and assigns, of and from any and all actions, causes of action, claims, counterclaims, debts, demands, liabilities, losses, and damages that, in any manner, relate to or arise out of any and all agreements among the Parties and any and all transactions, incidents, communications, and other dealings among the Parties as of the Effective Date. The Parties expressly acknowledge that this Agreement is intended to release all claims, whether liquidated or unliquidated, known or unknown to the Parties at the time of their signatures on the Agreement, and that this Agreement will extinguish any and all such claims. Nothing contained in this section shall release the Parties from compliance with this Agreement or be construed as an admission of liability by any Party.

7. Attorneys' Fees and Costs. The mutual releases herein shall expressly include any and all claims for attorneys' fees, costs, and expenses relating to the negotiation and execution of this Agreement, and each Party shall bear its own attorneys' fees. If any Party is required to take any action to enforce this Agreement, the court shall award reasonable attorneys' fees and costs to the prevailing Party.

8. Nondisparagement. As a material condition of this Agreement, the Parties agree not to disparage, directly or indirectly, orally or in writing, the other Parties or their respective agents, employees, affiliates, or any businesses or companies with which they are now or may become affiliated in the future.

9. Effectuation of Agreement. Each Party shall execute any and all documents and do and perform any and all acts and things necessary or proper to effectuate or further evidence the terms and provisions of this Agreement.

10. No Assignment of Claims. Each Party represents and warrants to the other Parties that it: (a) has not heretofore assigned or transferred, or purported to assign or transfer, to any person or entity any claims that it might have against any other Party; and (b) is the sole owner of all claims that it might have against any other Party and has full authority to release the claims and agree to all matters set forth in this Agreement.

2

11. Unknown Claims. The Parties acknowledge that they may have some claim, demand, or cause of action of which they are totally unaware and unsuspecting. It is the intention of the Parties in executing this Agreement that it will deprive them of any such claim and prevent them from asserting the same against any other Party. To this end, the Parties expressly waive any and all rights and benefits conferred upon them by any statute or at common law in any jurisdiction applicable hereto that would otherwise modify, limit, nullify, or prohibit the release granted hereby. The Parties covenant and agree to execute any further releases as may be required under any applicable statute or common law requirement in order to give full force and effect to this Agreement.

12. Complete Agreement; Modification; and Waiver. This Agreement constitutes the entire agreement among the Parties and supersedes all prior and contemporaneous agreements, representations, warranties, and understandings of the Parties. No supplement, modification, or amendment of this Agreement shall be binding unless executed in writing by all of the Parties. No waiver of any of the provisions of this Agreement shall be deemed or constitute a waiver of any other provision, whether or not similar, nor shall any waiver constitute a continuing waiver. No waiver shall be binding unless executed in writing by the Party making the waiver.

13. No Third-Party Beneficiaries. This Agreement is made and entered into for the sole benefit of the Parties hereto. No other person or entity shall be a direct or indirect beneficiary of, or have any direct or indirect claim in connection with, this Agreement.

14. Authorization. Each natural person signing this Agreement for or on behalf of any entity that is a Party to this Agreement does, by his signature, warrant and represent to the Parties to this Agreement: (a) that he is duly authorized by said entity to undertake such action on its behalf; (b) that all corporate or other action necessary to be taken by such entity to provide the authorization and to approve and authorize such entity to enter into and to perform this Agreement has been taken; (c) that his signature is the valid and binding act of that entity; and (d) that such entity is not the subject of any contract, order, or other document that would restrict such entity's authority to lawfully enter into and to perform this Agreement, and such entity has full power and authority to do so. Each natural person signing this Agreement on his own behalf represents and warrants to the Parties that he has full power and authority to execute and to perform this Agreement and that he is not the subject of any contract, order, or other document that would restrict his authority to lawfully enter into and to perform this Agreement.

15. Covenant Not To Sue. Each Party covenants and agrees that it will not at any time, directly or indirectly, initiate, maintain, or prosecute, or in any way knowingly aid in the initiation, maintenance, or prosecution, of any claim, demands, or cause of action, at law, in equity, or otherwise, against the other Parties or any of their respective officers, directors, employees, agents, successors, members, managers, or assigns for any claim, damage, loss, or injury of any kind arising out of or in any way connected with any transaction, agreement, occurrence, act, failure to act, statement, or omission respecting a release has been given herein. In furtherance of this covenant, each Party agrees that, except as may be required by an order of any court or governmental agency having jurisdiction, it will not make available to any third party any evidence, documents, or other information or materials in its possession or under its care, custody, or control, or in the possession, custody, or under the control of its counsel, which in any way relates to any transaction, agreement, occurrence, act, failure to act, statement, or omission, which is referred to or included within the scope of this release.

3

16. Independent Investigation. The Parties hereby declare, acknowledge, and agree that the terms of this Agreement have been read by them and discussed with their respective legal counsel, and that such terms are fully understood and voluntarily accepted for the purpose of making a full, final, and complete compromise, settlement, and adjustment of all transactions, agreements, arrangements, or courses of dealing. The Parties further acknowledge, declare, and agree that the facts and assumptions underlying this Agreement have been thoroughly investigated and reviewed by them and their respective counsel; that they are not relying upon any representations by any other Party hereto, but have entered into this Agreement based on their own independent investigation; and that this Agreement reflects the conclusion of such Party that this Agreement and the releases, waivers, and covenants contemplated herein are in the best interests of said Party.

17. No Admission of Liability. Neither this Agreement nor the negotiation, execution, or performance hereof shall be deemed to constitute an admission, directly or indirectly, by any Party of any liability or responsibility on account of, or respecting, any claims released herein, but this Agreement is entered into for the sole and exclusive purposes of resolving the disputes between the Parties, and each Party expressly denies any and all liability arising out of any of the claims, allegations, or demands whatsoever of any party against the other.

18. Survival. The representations, warranties, covenants, and agreements of the respective Parties set forth herein shall survive the Effective Date.

19. Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the state of Colorado, and the substantive laws of such state, excluding the principles of conflicts of laws, shall govern the validity, construction, enforcement, and interpretation of this Agreement, except insofar as federal laws shall have application.

20. Preparation of this Agreement and Construction of its Terms. The Parties agree that each of them has, personally or through their attorneys, participated in and contributed to the preparation of this Agreement. Each Party agrees that this Agreement shall be regarded and deemed as having been prepared jointly by the Parties. Any ambiguity or uncertainty existing herein shall not be interpreted or construed against any Party by virtue of who may have drafted such provision.

21. Further Actions. Each Party shall execute and deliver, or cause to be executed and delivered, such documents and instruments and shall take, or cause to be taken, such further or other actions as may be reasonably necessary to consummate and to effect the transactions contemplated by this Agreement.

22. Miscellaneous Provisions.

(a) This Agreement shall be binding upon and shall inure to the benefit of the Parties and the Parties' respective heirs, legal representatives, successors, and assigns.

(b) This Agreement may be executed in multiple counterparts, each of which shall constitute an original, and all of which together shall constitute one and the same document. The Parties will accept facsimile and electronically generated signatures as original signatures.

4

IN WITNESS WHEREOF, the undersigned have entered into and executed this Agreement as of the Effective Date.

 

	 CANNASYS, INC.	TAG DISTRIBUTING LLC, DBA CONSIGLIERE INC.
	 	 
	 By: /s/ Michael A. Tew	 By: /s/ Brett Harris
	        Michael A. Tew, President	        Brett Harris, Chief Executive Officer
	
 

	
 

	 LUVBUDS, LLC	 
	 By: /s/ Brett Harris	 
	        Brett Harris, Manager	
 

	 	 
	 /s/ Brett Harris	 
	 BRETT HARRIS, Individually	 

 

5ctxr_ex101.htm

EXHIBIT 10.1
 
EMPLOYMENT AGREEMENT
 
This EMPLOYMENT AGREEMENT (the "Agreement"), is entered into effective as of March 1, 2016 (the "Effective Date"), by and between Citius Pharmaceuticals, Inc., a Nevada corporation with principal executive offices at 63 Great Road, Maynard Massachusetts 01754 (the "Company"), and Myron Holubiak, residing at 1544 Edly Cove Court, North Brunswick, New Jersey 08902 (the "Executive").
 
W I T N E S S E T H:
 
WHEREAS, the Company desires to employ Executive as its Chief Executive Officer, and Executive desires to be employed by the Company, pursuant to the terms and conditions set forth herein.
 
NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties hereto hereby agree as follows:
 
1. Employment.
 
(a) Services. The Executive will be employed by the Company as its Chief Executive Officer. The Executive will report to the Board of Directors of the Company (the "Board") and shall perform such duties as are consistent with a position as Chief Executive Officer (the "Services"). The Executive agrees to perform such duties faithfully, to devote substantially all of his working time, attention and energies to the business of the Company, and while he remains employed and subject to the terms of this Agreement, not to engage in any other business activity that is in conflict with his duties and obligations to the Company. 
 
(b) Acceptance. Executive hereby accepts such employment and agrees to render the Services.
 
2. Term. The Executive's employment under this Agreement shall be deemed to commence on the Effective Date and shall continue for a term of three (3) years (the "Initial Term"), unless sooner terminated pursuant to Section 9 of this Agreement. This Agreement will automatically be extended for additional one (1) year periods (each an "Additional Term" and, together with the Initial Term, the "Term") unless the Company notifies the Executive in writing that it intends to not extend this Agreement at least sixty (60) days prior to the expiration of the then current Term; provided, however, that the Company's failure to provide the Executive with such notice shall not constitute termination by the Executive for Good Reason (as defined in Section 9(d) hereof).
 
3. Best Efforts. The Executive shall devote substantially all of his business time, attention and energies to the business and affairs of the Company and shall use his best efforts to advance the best interests of the Company and shall not during the Term be actively engaged in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary advantage, that will interfere with the performance by the Executive of his duties hereunder or the Executive's availability to perform such duties or that will adversely affect, or negatively reflect upon, the Company.   

	 
	1

	

	 

 
4. Directorship. The Company shall use its best efforts to cause Executive to be elected as a voting member of its Board throughout the Term and shall include him in the management slate for election as a director at every stockholders meeting during the Term at which his term as a director would otherwise expire. The Executive agrees to accept election, and to serve during the Term, as a member of the Board without any compensation therefore other than as specified in this Agreement.
 
5. Compensation. As full compensation for the performance by the Executive of his duties under this Agreement, the Company shall pay the Executive as follows:
 
(a) Base Salary. The Company shall pay Executive an annual salary (the "Base Salary") equal to Four Hundred and Fifty Thousand Dollars ($450,000) per year. Payment shall be made in accordance with the Company's normal payroll practices. The Base Salary will be reviewed by the Board no less frequently than annually.
 
(b) Annual Milestone Bonus. At the sole discretion of the Board, Executive may receive a discretionary bonus on each anniversary of the Effective Date during the Term (the "Annual Milestone Bonus") in an amount up to fifty percent (50%) of his then current Base Salary based on the attainment by the Executive of certain financial, clinical development and business milestones (the "Milestones") as established annually by the Board (or a committee thereof), after consultation with the Executive.The Annual Milestone Bonus shall be payable either as a lump-sum payment or in installments as determined by the Board in its sole discretion, provided, however, if the Board determines to pay the Executive in installments, such installments shall be no less frequently than monthly, and shall be over a time period not to exceed four (4) months, unless otherwise agreed by the Executive in writing. Notwithstanding the foregoing, the Annual Milestone Bonus, if any, for a given year will be paid in full no later than March 15 of the calendar year immediately following the calendar year for which the Annual Milestone Bonus, if any, is earned.
 
(c) Incentive Bonus. The Company shall pay the Executive periodic milestone-based incentive bonuses (each an "Incentive Bonus") of:
 
(i) In the event that the Market Capitalization (as defined below) of the Company shall exceed One Hundred Million Dollars (US$100,000,000) for a period of thirty (30) consecutive trading days during the Term (the "First Capitalization Milestone"), the Company shall pay to the Executive a cash bonus of Two Hundred Fifty Thousand Dollars ($250,000). For purposes of this Agreement, "Market Capitalization" shall be determined by multiplying the total shares of the Company's Common Stock which are issued and outstanding by the last reported closing price of the Company's Common Stock on a nationally recognized exchange, NASDAQ, or in the over-the-counter market as reported by the National Quotation Bureau or similar organization. This bonus will be paid in a lump sum as soon as it can be arranged by the Company, but in no event shall payment be made later than March 15 of the calendar year immediately following the calendar year that includes the thirtieth (30th) consecutive trading day on which the First Capitalization Milestone threshold is attained; and
 
(ii) In the event that the Market Capitalization of the Company shall exceed Two Hundred Fifty Million Dollars (US$250,000,000) for a period of thirty (30) consecutive trading days during the Term (the "Second Capitalization Milestone"), the Company shall pay to the Executive a cash bonus of Five Hundred Thousand Dollars ($500,000). This bonus will be paid in a lump sum as soon as it can be arranged by the Company, but in no event shall payment be made later than March 15 of the calendar year immediately following the calendar year that includes the thirtieth (30th) consecutive trading day on which the Second Capitalization Milestone threshold is attained.    

	 
	2

	

	 

 
(d) Withholding. The Company shall withhold all applicable federal, state and local taxes and social security and such other amounts as may be required by law from all amounts payable to the Executive under this Section 5.
 
(e) Expenses. The Company shall reimburse the Executive for all normal, usual and necessary expenses incurred by the Executive in furtherance of the business and affairs of the Company, including reasonable travel and entertainment, upon timely receipt by the Company of appropriate vouchers or other proof of the Executive's expenditures and otherwise in accordance with any expense reimbursement policy as may from time to time be adopted by the Company.
 
(f) Other Benefits. The Executive shall be entitled to all rights and benefits for which he shall be eligible under any benefit or other plans (including, without limitation, dental, medical, medical reimbursement and hospital plans, pension plans, employee stock purchase plans, profit sharing plans, bonus plans and other so-called "Fringe Benefits") as the Company shall make available to its senior executives from time to time. The Company shall also name Executive as a covered person under any Directors & Officers insurance policies. 
 
(g) Vacation. The Executive shall, during the Term, be entitled to a vacation of four (4) nonconsecutive weeks per annum, in addition to holidays observed by the Company. Unless otherwise provided by the Company's vacation policy, the Executive shall not be entitled to carry any unused, accrued vacation forward from one year of employment to the next, and any such vacation days will be forfeited without payment. In addition, the Executive will forfeit payment for any unused, accrued vacation upon termination of employment, subject to applicable law. 
 
6. Confidential Information and Inventions.
 
(a) The Executive recognizes and acknowledges that in the course of his duties he is likely to receive confidential or proprietary information owned by the Company or third parties with whom the Company has an obligation of confidentiality, relating to and used in the Company's business (collectively, "Confidential and Proprietary Information"). Confidential and Proprietary Information shall include, but shall not be limited to, confidential or proprietary scientific or technical information, data, formulas and related concepts, business plans (both current and under development), client lists, promotion and marketing programs, trade secrets, or any other confidential or proprietary business information relating to development programs, costs, revenues, marketing, investments, sales activities, promotions, credit and financial data, manufacturing processes, financing methods, plans or the business and affairs of the Company or of any affiliate or client of the Company, and any and all information relating to the operation of the Company's business which the Company may from time to time designate as confidential or proprietary or that Executive reasonably knows should be, or has been, treated by the Company as confidential or proprietary. The Executive expressly acknowledges that the Confidential and Proprietary Information constitutes a protectable business interest of the Company. The Executive further agrees that if any information that the Company deems to be a trade secret is found by a court of competent jurisdiction not to be a trade secret, such information will, nevertheless, be considered Confidential and Proprietary Information for purposes of this Agreement. Confidential and Proprietary Information does not include any information that: (i) at the time of disclosure is generally known to, or readily ascertainable by, the public; (ii) becomes known to the public through no fault of Executive or other violation of this Agreement; or (iii) is disclosed to Executive by a third party under no obligation to maintain the confidentiality of the information. The Executive agrees, during and after the Term, except as reasonably necessary for the fulfillment of his duties under this Agreement: (i) not to use any such Confidential and Proprietary Information for himself or others; (ii) to keep confidential and not disclose or make accessible to any other person or entity any Confidential and Proprietary Information; and (iii) not to take any Company Confidential and Proprietary Information (including but not limited to writings, correspondence, notes, drafts, records, invoices, technical and business policies, computer programs or disks) from the Company's offices at any time. The Executive agrees to return immediately all Company material and reproductions (including but not limited, to writings, correspondence, notes, drafts, records, invoices, technical and business policies, computer programs or disks) thereof in his possession to the Company upon termination of employment, or at any time upon the Company's request.   

	 
	3

	

	 

 
(b) Except with prior written authorization by the Company, the Executive agrees not to disclose or publish any of the Confidential and Proprietary Information, or any confidential, scientific, technical or business information of any other party to whom the Company owes an obligation of confidence, at any time during or after his employment with the Company. The restrictions in this Section 6(b) and in Section 6(a) above will not apply to any information that Executive is required to disclose by law, provided that Executive (i) notifies the Company of the existence and terms of such obligation, (ii) gives the Company a reasonable opportunity to seek a protective or similar order to prevent or limit such disclosure, and (iii) only discloses that information actually required to be disclosed. 
 
(c) The Executive agrees that all inventions, discoveries, improvements and patentable or copyrightable works ("Inventions") initiated, conceived or made by him, either alone or in conjunction with others, during the course of his employment by the Company or that result from work performed by Executive for the Company, shall be the sole property of the Company to the maximum extent permitted by applicable law and, to the extent permitted by law, shall be "works made for hire" as that term is defined in the United States Copyright Act (17 U.S.C.A., Section 101). The Company shall be the sole owner of all patents, copyrights, trade secret rights, and other intellectual property or other rights in connection therewith. The Executive hereby assigns to the Company all right, title and interest he may have or acquire in all such Inventions; provided, however, that the Board may in its sole discretion agree to waive the Company's rights pursuant to this Section 6(c) with respect to any Invention that is not directly or indirectly related to the Company's business. The Executive further agrees to assist the Company in every proper way (but at the Company's expense) to obtain and from time to time enforce patents, copyrights or other rights on such Inventions in any and all countries, and to that end the Executive will execute all documents necessary:
 
(i) to apply for, obtain and vest in the name of the Company alone (unless the Company otherwise directs) letters patent, copyrights or other analogous protection in any country throughout the world and when so obtained or vested to renew and restore the same; and
 
(ii) to defend any opposition proceedings in respect of such applications and any opposition proceedings or petitions or applications for revocation of such letters patent, copyright or other analogous protection.
 
(d) The Executive acknowledges that, while performing the services under this Agreement the Executive may locate, identify and/or evaluate patented or patentable inventions having commercial potential in the fields of pharmacy, pharmaceutical, biotechnology, healthcare, technology and other fields which may be of potential interest to the Company (the "Third-Party Inventions"). The Executive understands, acknowledges and agrees that all rights to, interests in or opportunities regarding, all Third-Party Inventions identified by the Company or either of the foregoing persons' officers, directors, employees (including the Executive), agents or consultants during the Term shall be and remain the sole and exclusive property of the Company or such affiliate and the Executive shall have no rights whatsoever to such Third-Party Inventions and will not pursue for himself or for others any transaction relating to the Third-Party Inventions which is not on behalf of the Company.
 
(e) The provisions of this Section 6 shall survive any termination or expiration of this Agreement.   

	 
	4

	

	 

 
7. Non-Competition and Non-Solicitation. The Executive understands and recognizes that his services to the Company are special and unique and that in the course of performing such services the Executive will have access to and knowledge of Confidential and Proprietary Information (as defined in Section 6) and will become knowledgeable of and familiar with the Company's customers as well as the Company's business. The Executive acknowledges that, due to the unique nature of the Company's business, the loss of any of its clients or business flow or the improper use of its Confidential and Proprietary Information could create significant instability and cause substantial damage to the Company and therefore the Company has a strong legitimate business interest in protecting the continuity of its business interests and the restriction herein agreed to by the Executive narrowly and fairly serves such an important and critical business interest of the Company. Therefore, Executive covenants and agrees as follow:
 
(a) Definitions. As used in this Agreement, the following terms have the meanings given to such terms below:
 
(i) "Business" means (A) acquiring, developing and commercializing drug products focused on adjunctive cancer therapies; (B) acquiring, developing and commercializing drug products for the treatment of hemorrhoids; and (C) any other business that the Company is actively engaged in at the time of the date of termination, provided that this clause (C) shall only apply if Executive is involved with that other business.
 
(ii) "Customer" means (A) any person or entity who is or was a customer of the Company at the time of, or during the six (6) month period prior to, the date of Executive's termination and with whom Executive had dealings on behalf of the Company in the course of his employment with the Company, or about whom Executive received Confidential and Proprietary Information in the course of his employment with the Company, and (B) any prospective customer to whom, within the six (6) month period prior to the Executive's date of termination, the Company had submitted proposals to for services of which Executive has knowledge, whether or not such proposals have yet to be executed into contracts, provided that, the Company has a legitimate expectation of doing business with such prospective customer, and provided further that the Executive has had material business contacts with such prospective customer on behalf of the Company, whether such contact was initiated by the prospective customer or by Executive.
 
(iii) "Company Employee" means (A) any person who is an employee of the Company at the time of the date of Executive's termination of employment, and (B) any person who was an employee of the Company during the six (6) month period prior to, the termination of Executive's employment.
 
(iv) "Person" means any person, firm, partnership, joint venture, corporation or other business entity.
 
(v) "Restricted Period" means the period commencing on the date of Executive's termination of employment and ending twelve (12) months thereafter, provided, however, that this period will be tolled and will not run during any time Executive is in violation of this Section 7, it being the intent of the parties that the Restricted Period will be extended for any period of time in which Executive is in violation of this Section.   

	 
	5

	

	 

 
(vi) "Restricted Territory" means any country in which the Company does business as of the Executive's date of termination, including without limitation each country to which the Executive directed or in which Executive performed employment-related activities on behalf of the Company at the time of, or during the six (6) month period prior to, the Executive's date of termination and each country in which the Company is actively preparing to conduct business within the six (6) month period immediately following the Executive's date of termination, provided that Executive is materially involved in such preparations; or if that geographic territory is deemed by a court of competent jurisdiction to be overly broad, the United States of America; or if that geographic territory is deemed by a court of competent jurisdiction to be overly broad, any state, province or similar geographic subdivision in which the Company does business as of the Executive's date of termination, including without limitation each state, province or similar geographic subdivision to which the Executive directed or in which Executive performed employment-related activities on behalf of the Company at the time of, or during the six (6) month period prior to, the date of termination. 
 
(b) Non-Competition. During his employment with the Company, Executive will not, on his own behalf or on behalf of any other Person, engage in any business competitive with or adverse to that of the Company. In addition, during his employment with the Company and during the Restricted Period, Executive will not (i) engage in the Business in the Restricted Territory, or (ii) hold a position based in or with responsibility for all or part of the Restricted Territory, with any Person engaging in the Business, whether as employee, consultant, or otherwise, (A) in which Executive will have duties, or will perform or be expected to perform services for such Person, that is or are the same as or substantially similar to the position held by Executive or those duties or services actually performed by Executive for the Company within the twelve (12) month period immediately preceding the Executive's date of termination, or (B) in which Executive will use or disclose or be reasonably expected to use or disclose any Confidential and Proprietary Information of the Company for the purpose of providing, or attempting to provide, such Person with a competitive advantage with respect to the Business. For purposes of clarification, nothing contained in this Section 7(b) shall be deemed to prohibit the Executive from acquiring or holding, solely for investment, publicly traded securities of any corporation, some or all of the activities of which are competitive with the business of the Company so long as such securities do not, in the aggregate, constitute more than five percent (5%) of any class or series of outstanding securities of such corporation.
 
(c) Non-Solicitation. During his employment with the Company and during the Restricted Period, Executive will not, directly or indirectly, on Executive's own behalf or on behalf of any other Person:
 
(i) Call upon, solicit, divert, encourage or attempt to call upon, solicit, divert or encourage any Customer for purposes of marketing, selling or providing products or services to such Customer that are similar to or competitive with those offered by the Company;
 
(ii) Induce, encourage or attempt to induce or encourage any Customer to reduce, limit or cancel its business with the Company; 
 
(iii) Induce, encourage or attempt to induce or encourage any Customer to purchase or accept products or services competitive with those offered by the Company from any Person (other than the Company) engaging in the Business;   

	 
	6

	

	 

 
(iv) Otherwise interfere or engage in any conduct that would have the effect of interfering, in any manner, with the business relationship between the Company and any of the Company's Customers; or
 
(v) Solicit, induce, or attempt to solicit or induce any Company Employee or any independent contractor (who is then engaged by the Company or was engaged by the Company in the prior six (6) months) to terminate his or her employment or engagement with the Company or to accept employment or engagement with any Person engaging in the Business within the Restricted Territory. 
 
(d) Direct Employment or Engagement by Customer. During his employment with the Company and during the Restricted Period, Executive will not be employed or engaged (as an employee, contractor, consultant or otherwise) directly by, or solicit employment or engagement by, any Person who, during the Term of this Agreement, was an agent or Customer of the Company with whom Executive worked during his employment with the Company in a position or capacity in which Executive will be performing services for such Customer that are the same as, or substantially similar to, those services provided by Executive for the Customer during Executive's employment with the Company. For the avoidance of doubt, the terms "agent" and "Customer" will not include any investment bank, investor, lender or other financial intermediary which may represent, invest in or otherwise deal with the Company.
 
(e) Enforcement. In the event that the Executive breaches or threatens to breach any provisions of Section 6 or this Section 7, then the Company will suffer irreparable harm and monetary damages would be inadequate to compensate the Company. Accordingly, in addition to any other rights which the Company may have, the Company shall (i) be entitled, without the posting of bond or other security, to seek injunctive relief to enforce the restrictions contained in such Sections and (ii) have the right to require the Executive to account for and pay over to the Company all compensation, profits, monies, accruals, increments and other benefits (collectively "Benefits") derived or received by the Executive as a result of any transaction constituting a breach of any of the provisions of Sections 6 or 7, to the maximum extent permitted by law.
 
(f) Reasonableness and Severability. Each of the rights and remedies enumerated in Section 7(e) shall be independent of the others and shall be in addition to and not in lieu of any other rights and remedies available to the Company at law or in equity. The Executive hereby acknowledges and agrees that the covenants provided for pursuant to Section 7 are essential elements of Executive's employment by the Company and are reasonable with respect to their duration, geographic area and scope and in all other respects. If, at the time of enforcement of this Section 7, a court holds that the restrictions stated herein are unreasonable under the circumstances then existing, the parties hereto agree that the maximum duration, scope or geographic area legally permissible under such circumstances will be substituted for the duration, scope or area stated herein. If any of the covenants contained in this Section 7, or any part of any of them, is hereafter construed or adjudicated to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants or rights or remedies which shall be given full effect without regard to the invalid portions. No such holding of invalidity or unenforceability in one jurisdiction shall bar or in any way affect the Company's right to the relief provided in this Section 7 or otherwise in the courts of any other state or jurisdiction within the geographical scope of such covenants as to breaches of such covenants in such other respective states or jurisdictions, such covenants being, for this purpose, severable into diverse and independent covenants.   

	 
	7

	

	 

 
(g) Remedies. In the event that an actual proceeding is brought in equity to enforce the provisions of Section 6 or this Section 7, the Executive shall not urge as a defense that there is an adequate remedy at law nor shall the Company be prevented from seeking any other remedies which may be available. The Executive agrees that he shall not raise in any proceeding brought to enforce the provisions of Section 6 or this Section 7 that the covenants contained in such Sections limit his ability to earn a living.
 
(h) Survival. The provisions of this Section 7 shall survive any termination of this Agreement.
 
8. Representations and Warranties. 
 
(a) The Executive hereby represents and warrants to the Company as follows:
 
(i) Neither the execution or delivery of this Agreement nor the performance by the Executive of his duties and other obligations hereunder violate or will violate any statute, law, determination or award, or conflict with or constitute a default or breach of any covenant or obligation under (whether immediately, upon the giving of notice or lapse of time or both) any prior employment agreement, contract, or other instrument to which the Executive is a party or by which he is bound.
 
(ii) The Executive has the full right, power and legal capacity to enter and deliver this Agreement and to perform his duties and other obligations hereunder. This Agreement constitutes the legal, valid and binding obligation of the Executive enforceable against him in accordance with its terms. No approvals or consents of any persons or entities are required for the Executive to execute and deliver this Agreement or perform his duties and other obligations hereunder.
 
(b) The Company hereby represents and warrants to the Executive that this Agreement and the employment of the Executive hereunder have been duly authorized by and on behalf of the Company, including, without limitation, by all required action by the Board.
 
9. Termination. The Executive's employment hereunder shall be terminated immediately upon the Executive's death and may be otherwise terminated as follows:
 
(a) The Executive's employment hereunder may be terminated by the Board for Cause. Any of the following actions by the Executive shall constitute "Cause":
 
(i) The willful failure, disregard or continuing refusal by the Executive to perform his duties hereunder;
 
(ii) Any act of willful or intentional misconduct, or a grossly negligent act by the Executive having the effect of injuring, in a material way (as determined in good-faith by a majority of the Board), the business or reputation of the Company, including but not limited to, any officer, director, or executive of the Company;     

	 
	8

	

	 

 
(iii) Willful misconduct by the Executive in carrying out his duties or obligations under this Agreement, including, without limitation, insubordination with respect to lawful directions received by the Executive from the Board;
 
(iv) The Executive's indictment of any felony or a misdemeanor involving moral turpitude (including entry of a nolo contendere plea);
 
(v) The determination by the Board, based upon clear and convincing evidence, after a reasonable and good-faith investigation by the Company following a written allegation by another employee of the Company, that the Executive engaged in some form of harassment prohibited by law (including, without limitation, age, sex or race discrimination), unless the Executive's actions were specifically directed by the Board;
 
(vi) Any intentional misappropriation of the property of the Company, or embezzlement of its funds or assets (whether or not a misdemeanor or felony);
 
(vii) Breach by the Executive of any of the provisions of Sections 6, 7 or 8 of this Agreement; and
 
(viii) Breach by the Executive of any provision of this Agreement other than those contained in Sections 6, 7 or 8 which is not cured by the Executive within thirty (30) business days after notice thereof is given to the Executive by the Company.
 
Except as otherwise expressly provided for in this Section 9(a), any determination of Cause under Section 9(a) will be made by two-thirds of the Board voting on such determination. With respect to any such determination, the Board will act fairly and in utmost good faith and will give the Executive and his counsel an opportunity to appear and be heard at a meeting of the Board, and present evidence on the Executive's behalf. 
 
(b) The Executive's employment hereunder may be terminated by the Board due to the Executive's Disability. For purposes of this Agreement, a termination for "Disability" shall occur (i) when the Board has provided a written termination notice to the Executive supported by a written statement from a reputable independent physician mutually selected by the Company and the Executive, or the Executive's legal representatives in the event he is unable to make such selection due to physical or mental incapacity, to the effect that the Executive shall have become so physically or mentally incapacitated as to be unable to resume, even with reasonable accommodation as may be required under the Americans With Disabilities Act, within the ensuing twelve (12) months, his employment hereunder by reason of physical or mental illness or injury, or (ii) upon rendering of a written termination notice by the Board after the Executive has been unable to substantially perform his duties hereunder, even with reasonable accommodation as may be required under the Americans With Disabilities Act, for 120 or more consecutive days, or more than 180 days in any consecutive twelve month period, by reason of any physical or mental illness or injury. For purposes of this Section 9(b), the Executive agrees to make himself available and to cooperate in any reasonable examination by a reputable independent physician mutually selected by the Company and the Executive, and paid for by the Company. Notwithstanding the foregoing, nothing herein shall give the Company the right to terminate Executive prior to discharging its obligations to Executive, if any, under the Family and Medical Leave Act, the Americans With Disabilities Act, or any other applicable law. The Company shall reimburse Executive for his actual cost of maintaining a supplementary long-term disability insurance policy during the Term up to a maximum reimbursement of $10,000 per year. 
 

	 
	9

	

	 

 
(c) The Executive's employment hereunder may be terminated by the Board (or its successor) by written notice to the Executive upon the occurrence of a Change of Control. For purposes of this Agreement, "Change of Control" means (i) the acquisition, directly or indirectly, following the date hereof by any person (as such term is defined in Section 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended), in one transaction or a series of related transactions, of securities of the Company representing in excess of fifty percent (50%) or more of the combined voting power of the Company's then outstanding securities if such person or his or its affiliate(s) do not own in excess of 50% of such voting power on the Effective Date of this Agreement, or (ii) the future disposition by the Company (whether direct or indirect, by sale of assets or stock, merger, consolidation or otherwise) of all or substantially all of its business and/or assets in one transaction or series of related transactions other than a merger (1) effected exclusively for the purpose of changing the domicile of the Company or (2) effected for the purpose of obtaining a public listing and/or publicly traded securities.
 
(d) The Executive's employment hereunder may be voluntarily terminated by the Executive for Good Reason. For purposes of this Agreement, "Good Reason" shall mean any of the following: (i) any material reduction by the Company of the Executive's duties, responsibilities, or authority as Chief Executive Officer of the Company which causes his position with the Company to become of less responsibility or authority than his position immediately following the Effective Date; (ii) any material reduction by the Company of the Executive's compensation or benefits payable hereunder (it being understood that a reduction of benefits applicable to all employees of the Company, including the Executive, shall not be deemed a reduction of the Executive's compensation package for purposes of this definition); (iii) any requirement by the Company that the Executive locate Company headquarters, or Executive's residence or primary place of employment, to a location outside a 30-mile radius of Cranford, New Jersey, or (iv) failure during the Term to nominate the Executive for election to the Board and to recommend to shareholders to vote in support of such nomination, or failure of the Board to appoint the Executive as Chief Executive Officer of the Company, or removal during the Term from the Board or as Chief Executive Officer of the Company, provided that such failure or removal is not in connection with either: (x) a termination of the Executive's employment hereunder by the Company for Cause, or (y) as a result of the failure of the stockholders of the Company to elect the Executive to the Board despite the Company's compliance with its obligations under Section 4 hereof; (v) a material breach by the Company of Section 8(b) of this Agreement which is not cured by the Company within 30 days after written notice thereof is given to the Company by the Executive, or (vi) a change in the lines of reporting such that the Executive no longer reports directly to the Board. However, notwithstanding the above, Good Reason shall not exist unless: (x) the Executive notifies the Board within ninety (90) days of the initial existence of one of the adverse events described above, and (y) the Company fails to correct the adverse event within thirty (30) days of such notice, and (z) the Executive's voluntary termination because of the existence of one or more of the adverse events described above occurs within 24 months of the initial existence of the event.
 
(e) The Executive's employment may be terminated by the Company without Cause by delivery of written notice to the Executive effective fifteen (15) days after the date of delivery of such notice.
 
(f) The Executive's employment may be terminated by the Executive in the absence of Good Reason by delivery of written notice to the Company effective fifteen (15) days after the date of delivery of such notice.   

	 
	10

	

	 

 
10. Compensation upon Termination.
 
(a) Accrued Benefits. Upon termination of Executive's employment by either party regardless of the cause or reason, Executive shall be entitled to the following, referred to herein as the "Accrued Benefits": (i) payment for any accrued, unpaid Base Salary through the termination date; (ii) payment for any Incentive Bonus earned and payable but not yet paid as of the date of termination, if any; and (iii) reimbursement for any approved business expenses that Executive has timely submitted for reimbursement in accordance with the Company's business expense reimbursement policy or practice. Except as otherwise expressly provided by this Agreement, the Company shall have no further payment obligations to Executive upon the termination of his employment.
 
(b) Change of Control Severance. If the Executive's employment is terminated by the Company during the Term in connection with or within six (6) months following the occurrence of a Change of Control, provided that Executive signs and does not revoke a general release of claims against the Company within the time period specified therein, in form and substance satisfactory to the Company (the "Release"), and provided further that such termination is a "separation from service" within the meaning of Treasury Regulation § 1.409A-1(h), then the Company shall provide the following benefits to Executive, referred to herein as the "Change of Control Separation Benefits": (i) a lump sum payment equal to eighteen (18) months of Executive's then-current Base Salary (less applicable taxes and withholdings); (ii) the full Annual Milestone Bonus (items (i) and (ii) being the "Change of Control Separation Pay"); and (iii) provided that Executive properly and timely elects to continue his health insurance benefits under COBRA or applicable state continuation coverage law after the date of termination, reimbursement for Executive's applicable health continuation coverage premiums for a period of eighteen (18) months or until Executive becomes eligible for insurance benefits from another employer, whichever is earlier (the "Change of Control COBRA Reimbursement"). The Change of Control Separation Pay will be paid on the Company's first regular payday occurring sixty (60) days after the termination date. The Change of Control COBRA Reimbursement shall continue for the specified period provided that the Company has the right to discontinue the reimbursement payment and pay to the Executive a lump sum amount equal to the current COBRA premium times the number of months remaining in the specified period if the Company determines that continued payment of the COBRA reimbursement is discriminatory under Section 105(h) of the Internal Revenue Code.
 
(c) Other Severance Benefits. If the Executive's employment is terminated during the Term as a result of Executive's Disability pursuant to Section 9(b), by the Company without Cause pursuant to Section 9(e), or by Executive for Good Reason pursuant to Section 9(d), provided that Executive signs and does not revoke the Release within the time period specified therein, and provided further that such termination is a "separation from service" within the meaning of Treasury Regulation § 1.409A-1(h), then the Company shall provide the following benefits to Executive, referred to herein as the "Separation Benefits": (i) the continued payment in installments of Executive's then-current Base Salary (less applicable taxes and withholdings) for a period of twelve (12) months following the date of termination (the "Separation Pay"); and (ii) provided that Executive properly and timely elects to continue his health insurance benefits under COBRA or applicable state continuation coverage law after the date of termination, reimbursement for Executive's applicable health continuation coverage premiums for a period of twelve (12) months or until Executive becomes eligible for insurance benefits from another employer, whichever is earlier (the "COBRA Reimbursement"). The first installment of the Separation Pay will be paid on the Company's first regular payday occurring sixty (60) days after the termination date in an amount equal to the sum of payments of Base Salary that would have been paid if he had remained in employment for the period from the termination date through the payment date. The remaining installments will be paid until the end of the 12-month period at the same rate as the Base Salary in accordance with the Company's normal payroll practices for its employees. The COBRA Reimbursement shall continue for the specified period provided that the Company has the right to discontinue the reimbursement payment and pay to the Executive a lump sum amount equal to the current COBRA premium times the number of months remaining in the specified period if the Company determines that continued payment of the COBRA reimbursement is discriminatory under Section 105(h) of the Internal Revenue Code. Executive understands that if he is eligible to receive the Separation Benefits, such Separation Benefits shall be in lieu of and not in addition to any other severance benefits otherwise provided for herein, including the severance benefits described in Section 10(b) of this Agreement. Notwithstanding the foregoing, if Executive is entitled to receive the Separation Benefits but violates any provisions of this Agreement or any other agreement entered into by Executive and the Company after termination of employment, the Company will be entitled to immediately stop paying any further installments of the Separation Benefits. If the Executive's employment is terminated during the Term as a result of Executive's death, then the Company shall provide to Executive's estate the continued payment of Executive's then-current Base Salary for a period of twelve (12) months following the date of termination, beginning on the Company's first regular payday following the date of such termination.     

	 
	11

	

	 

 
(d) This Section 10 sets forth the only obligations of the Company with respect to the termination of the Executive's employment with the Company, except as otherwise required by law, and the Executive acknowledges that, upon the termination of his employment, he shall not be entitled to any payments or benefits which are not explicitly provided in Section 10. For purposes of clarification, if Executive's employment with the Company terminates upon expiration of the Term, Executive shall only be entitled to receive the Accrued Benefits described in Section 10(a).
 
(e) Upon termination of the Executive's employment hereunder for any reason, the Executive shall be deemed to have resigned as director of the Company, effective as of the date of such termination.
 
(f) The provisions of this Section 10 shall survive any termination of this Agreement.
 
11. 409A Restrictions. The intent of the parties to the Agreement is that the payments, compensation and benefits under this Agreement be exempt from or comply with Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively, "Section 409A") and, in this connection, the following shall be applicable:
 
(a) To the greatest extent possible, this Agreement shall be interpreted to be exempt or in compliance with Section 409A. 
 
(b) If any severance, compensation, or benefit required by the Agreement is to be paid in a series of installment payments, each individual payment in the series shall be considered a separate payment for purposes of Section 409A.
 
(c) If any severance, compensation, or benefit required by the Agreement that constitutes "nonqualified deferred compensation" within the meaning of Section 409A is considered to be paid on account of "separation from service" within the meaning of Section 409A, and Executive is a "specified employee" within the meaning of Section 409A, no payments of any of such severance, compensation, or benefit shall made for six (6) months plus one (1) day after such separation from service (the "New Payment Date"). The aggregate of any such payments that would have otherwise been paid during the period between the date of separation from service and the New Payment Date shall be paid to the Executive in a lump sum on the New Payment Date. Thereafter, any severance, compensation, or benefit required by the Agreement that remains outstanding as of the day immediately following the New Payment Date shall be paid without delay over the time period originally scheduled, in accordance with the terms of this Agreement.
 
(d) The provisions of this Section 11 shall survive any termination of this Agreement.

 
12. Miscellaneous.
 
(a) This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of New Jersey, without giving effect to its principles of conflicts of laws.
 
(b) The parties agree that any litigation arising out of or related to this Agreement or Executive's employment by the Company will be brought exclusively in any state or federal court in Union County, New Jersey. Each party (i) consents to the personal jurisdiction of said courts, (ii) waives any venue or inconvenient forum defense to any proceeding maintained in such courts, and (iii) agrees not to bring any proceeding arising out of or relating to this Agreement or Executive's employment by Company in any other court.   

	 
	12

	

	 

 
(c) This Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective heirs, legal representatives, successors and permitted assigns.
 
(d) This Agreement, and the Executive's rights and obligations hereunder, may not be assigned by the Executive. The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company, including any successors or assigns in connection with any sale, transfer or other disposition of all or substantially all of its business or assets.
 
(e) This Agreement cannot be amended orally, or by any course of conduct or dealing, but only by a written agreement signed by the parties hereto.
 
(f) The failure of either party to insist upon the strict performance of any of the terms, conditions and provisions of this Agreement shall not be construed as a waiver or relinquishment of future compliance therewith, and such terms, conditions and provisions shall remain in full force and effect. No waiver of any term or condition of this Agreement on the part of either party shall be effective for any purpose whatsoever unless such waiver is in writing and signed by such party.
 
(g) All notices, requests, consents and other communications, required or permitted to be given hereunder, shall be in writing and shall be delivered personally or by an overnight courier service or sent by registered or certified mail, postage prepaid, return receipt requested, to the parties at the addresses set forth on the first page of this Agreement, and shall be deemed given when so delivered personally or by overnight courier, or, if mailed, five days after the date of deposit in the United States mails. Either party may designate another address, for receipt of notices hereunder by giving notice to the other party in accordance with this Section 12 (g).
 
(h) This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter hereof, and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter hereof. No representation, promise or inducement has been made by either party that is not embodied in this Agreement, and neither party shall be bound by or liable for any alleged representation, promise or inducement not so set forth.
 
(i) As used in this Agreement, "affiliate" of a specified person or entity shall mean and include any person or entity controlling, controlled by or under common control with the specified person or entity.
 
(j) The section headings contained herein are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement.
 
(k) This Agreement may be executed in any number of counterparts, each of which shall constitute an original, but all of which together shall constitute one and the same instrument.
 
[Remainder of Page Intentionally Left Blank – Signature Page Follows]
     

	 
	13

	

	 

 
IN WITNESS WHEREOF, the parties hereto have executed this Agreement and intend it to be effective as of the Effective Date by proper person thereunto duly authorized.

    	 
	CITIUS PHARMACEUTICALS, INC.	 

	 	 	 	 
		By:	/s/ Leonard Mazur	 

	 
	Name: 
	Leonard Mazur
	 

	 
	Title: 
	Chairman of the Board
	 

	 
	 
	 
	 

	 
	EXECUTIVE  
	 

	 
	 
	 
	 

	 
	 
	/s/ Myron Holubiak
	 

	 
	 
	Myron Holubiak
	 

 
 
14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]